• Age ≥ 18 years old

• ECOG performance status ≤ 2

• Female and Male

• Newly diagnosed, histologically confirmed primary squamous cell carcinoma of the oropharynx

• Candidate for curative intent radiotherapy and systemic treatment

• No prior or current anticancer treatment for the HNSCC (e.g. neo-adjuvant chemotherapy, surgery)

• Diagnosis biopsy results

• HPV/p 16 testing results

• Serum test (for subjects of childbearing potential) negative within 7 days prior to the 1st CRT administration.

⁃ Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least 6 months after the last administration of cisplatin.

⁃ Men with childbearing potential partner must agree to use condom during the course of this study and for at least 6 months after the last administration of the cisplatin.

⁃ Adequate bone marrow function as defined below:

∙ Absolute neutrophil count (ANC) ≥1500/µL or 1.5x109/L

‣ Hemoglobin ≥ 9 g/dL

‣ Platelets ≥100000/µL or 100x109/L

⁃ Adequate liver function as defined below:

∙ Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome \< 3 x UNL is allowed

‣ AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN

‣ Alkaline phosphatase ≤ 2.5 x ULN

⁃ Adequate renal function as defined below:

∙ Creatinine ≤ 1.5 x UNL and creatinine clearance \> 60 mL/min

⁃ Peripheral neuropathy ≤ grade 1

⁃ Hear impaired ≤ grade 1

⁃ Completion of all necessary screening procedures within 15 days prior to randomisation.

⁃ Signed Informed Consent form (ICF) obtained prior to any study related procedure.

⁃ Ability to understand and complete the questionnaires (language proficiency, cognitive functioning) as judged by principal investigator upon screening